에 대한 최신 뉴스 GeneDx Hldgs (NASDAQ:WGS) 주식

GeneDx Hldgs

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Mid Cap

News

Topics

Movers

Trading Ideas

AAPL

GSAT

MDGL

OMCL

PRCT

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 마드리갈 파마슈티컬스(NASDAQ:MDGL)의 주식은 회사가 예상보다 좋은 실적을 발표한 후 51.70% 상승했다.

글로벌스타와 넥스트래커는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 28일-11월 1일)

Earnings

진Dx 홀딩스(NASDAQ:WGS)가 월요일 시장 마감 후 1분기 재무 결과를 보고한 후 주가가 급등했다. 주요 내용을 살펴보자. 주요 사항 (The Details): 진Dx(GeneDx)는 분기 손실을 주당 33센트로 보고했는데, 이는 분석가의 합의 손실 추정치인 67센트를 50.75%나 앞선 것이다.

진DX: 예상보다 좋은 1분기 실적 및 연간 전망 상향 조정 후 주가 급등

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings Corp

WIIM

LAES

SEALSQ shares are trading higher after the company late Thursday announced it has received formal confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement.

ALERT OCCURS AFTER EARLY WEAKNESS IN STOCK
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="745" height="602" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/26210621/Screen-Shot-2024-12-26-at-4.08.57-PM.png" alt="" class="wp-image-4287" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/26210621/Screen-Shot-2024-12-26-at-4.08.57-PM.png 745w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/26210621/Screen-Shot-2024-12-26-at-4.08.57-PM-300x242.png 300w" sizes="(max-width: 745px) 100vw, 745px" /></figure>
Microstrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
At 10:05 AM on December 26th, a significant trading signal occurred for Microstrategy , Inc. (MSTR) as it demonstrated a Power Inflow at a price of $343.47. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Microstrategy&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Microstrategy&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for MSTR, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $343.47. The returns on the High price ($349.68) and Close price ($341.05) after the Power Inflow were respectively 1.9% and -0.7%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. 
Past Performance is Not Indicative of Future Results

MSTR

TradePulse Power Inflow Alert: Microstrategy Inc. (MSTR) Moves up 1.8% After Signal

MYSZ

MySize shares are trading higher after the company announced it anticipates closing 2024 with $8.5 million in revenue and targets $15 million in revenue by 2025.

OTLK

Outlook Therapeutics 2024 EPS $(4.06) vs $(4.72) YoY

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.68</td>
<td align="right">0.11</td>
<td align="right">0.13</td>
<td>1.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.75</td>
<td align="right">0.06</td>
<td align="right">0.07</td>
<td>273</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">232.80</td>
<td align="right">-0.80</td>
<td align="right">-0.35</td>
<td>655</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.94</td>
<td align="right">-0.17</td>
<td align="right">-0.35</td>
<td>40.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">139.37</td>
<td align="right">-0.23</td>
<td align="right">-0.17</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">240.43</td>
<td align="right">-0.26</td>
<td align="right">-0.11</td>
<td>7.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">99.00</td>
<td align="right">-0.04</td>
<td align="right">-0.05</td>
<td>720</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 27, 2024

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

Price Target

Analyst Ratings

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

Guidance

MySize Anticipates Closing 2024 With $8.5M In Revenue, Targets $15M In Revenue By 2025

On December&nbsp;24, 2024, Sichuan Jiade Zhigao Technology Co.,&nbsp;Ltd., a limited liability company organized under the laws of the PRC ("Jiade Zhigao"), which is a PRC subsidiary of JIADE LIMITED, a Cayman Islands company (the "Company"), entered into an equity transfer agreement (the "Kunyuan Agreement") with Chengdu Meirusi Technology Co.,&nbsp;Ltd. ("Meirusi"), which is a PRC limited liability company holding 75% of the equity interests in Sichuan Kunyuan Safety Technology Services Co.,&nbsp;Ltd. ("Kunyuan"). Pursuant to the Kunyuan Agreement, Jiade Zhigao agreed to acquire 75% of the equity interests in Kunyuan from Meirusi (the "First Acquisition"). In consideration for the First Acquisition, Jiade Zhigao agreed to pay RMB9,000,000 (approximately $1,234,000) to Meirusi, subject to the satisfaction by Meirusi and Kunyuan of their obligations under the Kunyuan Agreement. The Kunyuan Agreement contains customary covenants, closing conditions, and other obligations and rights of the parties.
On December&nbsp;24, 2024, Jiade Zhigao also entered into an equity transfer agreement (the "Jiazhi Agreement") with Meirusi, the sole shareholder of Sichuan Jiazhi Taizhang Safety Technology Co.,&nbsp;Ltd. ("Jiazhi"). Pursuant to the Jiazhi Agreement, Jiade Zhigao agreed to acquire 100% of the equity interests in Jiazhi from Meirusi (the "Second Acquisition"). In consideration for the Second Acquisition, Jiade Zhigao agreed to pay RMB23,000,000 (approximately $3,153,000) to Meirusi, subject to the satisfaction by Meirusi and Jiazhi of their obligations under the Jiazhi Agreement. The Jiazhi Agreement contains customary covenants, closing conditions, and other obligations and rights of the parties.
The foregoing description of the Kunyuan Agreement and the Jiazhi Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Kunyuan Agreement and the Jiazhi Agreement, which are filed as Exhibit&nbsp;10.1 and Exhibit&nbsp;10.2 to this Form&nbsp;6-K, respectively.
The Kunyuan and Jiazhi Agreements and the transactions contemplated thereby were approved and authorized by the board of directors of the Company on December&nbsp;23, 2024.

JDZG

Sichuan Jiade Zhigao Technology Co. Entered Equity Transfer Agreement With Chengdu Meirusi Technology Co., Under Which Jiade Zhigao Agreed To Acquire 75% Of Equity Interests In Kunyuan From Meirusi; Jiade Zhigao Also Entered Equity Transfer Agreement To Acquire 100% Of The Equity Interests In Jiazhi From Meirusi

BFRG

BullFrog AI Issues Letter to Stockholders: Reflects on Milestones in 2024, Strengthens AI-Driven Drug Development and Expands Collaborations for 2025 Growth

GXAI

Gaxos.ai Announces $4M Registered Direct Offering: Inks Pacts For The Purchase And Sale Of An Aggregate Of 1.34M Shares Of Common Stock At A Purchase Price Of $3.00 Per Share In A Registered Direct Offering Priced At-the-market Under Nasdaq Rules

Management

FAST

Fastenal Announces Senior Executive Vice President And Chief Financial Officer Holden Lewis Provided Notice Of His Resignation, Effective On Apr. 16, 2025

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $184.75, a high estimate of $210.00, and a low estimate of $170.00. Surpassing the previous average price target of $168.86, the current average has increased by 9.41%.
<img src="https://www.benzinga.com/files/images/story/2024/1735304440_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Masimo among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$194.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$193.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Masimo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Masimo compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Masimo's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Masimo's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MASI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Masimo analyst ratings.</a>
<h2>Discovering Masimo: A Closer Look</h2>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Masimo's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Masimo showcased positive performance, achieving a revenue growth rate of 5.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Masimo's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Masimo's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Masimo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Masimo's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.59, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MASI

What Analysts Are Saying About Masimo Stock

KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.45, a high estimate of $41.00, and a low estimate of $30.00. This current average represents a 0.89% decrease from the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1735304428_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of KinderCare Learning among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Faiza Alwy</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KinderCare Learning. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KinderCare Learning compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of KinderCare Learning's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into KinderCare Learning's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KLC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on KinderCare Learning analyst ratings.</a>
<h2>Get to Know KinderCare Learning Better</h2>
KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market- leading footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its three go-to-market channels are KinderCare Learning Centers, KinderCare Education at Work, and Champions.
<h3>Financial Insights: KinderCare Learning</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: KinderCare Learning's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 7.53%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: KinderCare Learning's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.08% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): KinderCare Learning's ROE stands out, surpassing industry averages. With an impressive ROE of 5.9%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): KinderCare Learning's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.38%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 12.62, KinderCare Learning faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For KinderCare Learning

In the latest quarter, 10 analysts provided ratings for Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bright Horizons Family, revealing an average target of $136.1, a high estimate of $162.00, and a low estimate of $102.00. Witnessing a positive shift, the current average has risen by 2.33% from the previous average price target of $133.00.
<img src="https://www.benzinga.com/files/images/story/2024/1735304416_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bright Horizons Family. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$102.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$128.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bright Horizons Family. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bright Horizons Family compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bright Horizons Family's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Bright Horizons Family's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BFAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bright Horizons Family analyst ratings.</a>
<h2>About Bright Horizons Family</h2>
Bright Horizons Family Solutions Inc provides education and care solutions designed to help employers support their employees in managing their work/life balance. The company has three business segments: full-service center-based child care, backup care, and educational advisory services. The vast majority of the company's revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, tuition assistance, and education consulting. The company earns more than half of its revenue in North America.
<h3>Bright Horizons Family's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Bright Horizons Family's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.35%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bright Horizons Family's ROE excels beyond industry benchmarks, reaching 4.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.42%, the company showcases effective utilization of assets.
Debt Management: Bright Horizons Family's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFAM

Beyond The Numbers: 10 Analysts Discuss Bright Horizons Family Stock

Takeda Pharmaceutical Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase) for the treatment of patients <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42697319/takeda-announces-approval-of-hyqvia-10-s-c-subcutaneous-injection-set-in-japan-for-patients-with-a" rel="noreferrer noopener">with agammaglobulinemia or hypogammaglobulinemia.</a>
These conditions, characterized by low or absent antibody levels, result in an increased risk of serious infections. This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option.
HYQVIA combines subcutaneous immunoglobulin (10%) with recombinant human hyaluronidase (rHuPH20), which facilitates larger volume infusions by increasing the dispersion and absorption of immunoglobulin in subcutaneous tissue.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42696705/bitcoin-ethereum-dogecoin-retreat-after-christmas-surge-top-analyst-highlights-what-btc-needs-to-do-to-invalidate-bearish-outlook" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Pull Back After Christmas Rally: Top Analyst Reveals What Happens Next After BTC Fails To Record Daily Close Above $100K</a>
This allows for less frequent dosing, with treatments every 3 to 4 weeks, compared to weekly or bi-weekly infusions with other subcutaneous immunoglobulin treatments.
This flexibility eliminates the need for venous access, offering patients greater convenience.
The approval was based on data from two Phase 3 clinical trials conducted in Japan and North America.
These studies showed that HYQVIA maintained stable IgG levels comparable to intravenous or other subcutaneous immunoglobulin treatments, with manageable side effects such as mild fever and injection site reactions.
Takeda's commitment to offering differentiated immunoglobulin therapies is further demonstrated by this approval, which expands its portfolio in Japan.
The company also continues to invest in local manufacturing to meet the growing demand for plasma-derived therapies as education and diagnosis of immunodeficiencies improve.
Price Action: TAK shares are trading higher by 1.07% to $13.28&nbsp;premarket at last check Friday.
Read Next:&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42690488/are-donald-trumps-ambitious-bitcoin-goals-feasible" target="_blank" rel="noreferrer noopener">Are Donald Trump's Ambitious Bitcoin Goals Feasible?</a></li>
</ul>

Asia

Equities

Markets

General

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

UBS analyst Jay Sole reiterates On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and maintains $63 price target.

Reiteration

ONON

UBS Reiterates Buy on On Holding, Maintains $63 Price Target

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $119 to $130.

MMYT

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $130

EVject first came into focus after EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) sued it over the safety of its &#8216;breakaway&#8217; <a href="https://www.benzinga.com/news/24/07/39951183/tesla-supercharger-network-growth-slows-down-in-q2-after-exit-of-rebecca-tinucci-and-other-employees" target="_blank" rel="noreferrer noopener">charging connector for EV drivers.</a>
EVject's charging connector allows drivers to disconnect from EV chargers and drive away in emergencies without stepping out of the vehicle. Tesla filed a lawsuit against EVject earlier this year alleging that their breakaway connectors are "dangerous" and pose a high safety risk.
Inspiration Behind The Breakaway Connector: EVject founder Kreg Peeler in an interview detailed the inspiration behind the connector. 
&#8220;We came into existence because we kept hearing about this problem where it&#8217;s not just Teslas, but all EVs. Any electric vehicle plugged in at a public charger is disabled while charging,&#8221; Peeler said. 
Tesla&#8217;s Lawsuit: The company developed its breakaway connector device and shipped all its preorders in February earlier this year before it received a notice from Tesla. Tesla subsequently requested a few EVject connectors to test and said it has no over-temperature protection and may overheat when charging.
Peeler subsequently took to X noting his differences with the testing and Tesla CEO Elon Musk assured in a post on X that he &#8220;will investigate&#8221; the issue. 
Tesla later reached out to Peeler and EVject agreed to have a thermal sensor included in the product as a protective measure in case of overheating and the EV maker subsequently dropped the lawsuit. 
Boon In Disguise?: As per Peeler, it would cost EVJect $30,000 to get the connectors shipped to customers back and then retrofit them with thermal sensors before sending them back out.
&#8220;It&#8217;s about $30,000. But overall, we think the market exposure and the awareness we got out of it was probably worth that,&#8221; Peeler said.
The lawsuit threw EVject into the spotlight, with several players showing interest in the company&#8217;s connector device, including German automaker Volkswagen.
The company is now looking forward to showcasing a few of its products to Volkswagen in March. 
EVject has shipped 3,500 of its breakaway connectors to date. While the company is making a profit per device, it is yet to be profitable as a corporation. The company is now looking to scale in terms of volume and has also got ideas for new products to develop when they have enough cash flow.
&#8220;By 2030, we want to have sold millions of units and have the company be worth a billion dollars. So that&#8217;s five years away. Or get acquired somewhere along the way. If Volkswagen or Tesla came in and made us a good offer, we would seriously consider it,&#8221; Peeler said. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy" target="_blank" rel="noreferrer noopener">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a></li>
</ul>
Photo courtesy: EVject

Tech

TSLA

Tesla's Lawsuit Has Startup EVject Looking At A Potential Partnership With Volkswagen

U.S. equity markets could be headed for a correction due to a confluence of factors like the growing divergence from "Magnificent 7" stocks and President-elect Donald Trump's tariff plans, according to market expert Jay Woods.
What Happened: In an interview with <a href="https://www.cnbc.com/video/2024/12/27/market-is-at-the-beginning-of-a-10-percent-correction-says-freedom-capitals-jay-woods.html">CNBC</a>, Woods, chief market strategist at Freedom Capital Markets, cautioned about the possibility of a market correction in the near term.
According to Woods, we could be at the beginning of a 10% correction in the equity markets. Woods noted that these corrections happen roughly once every 18 months.
"We've had a tremendous run, 10% correction is due to happen every 18 months… What we're seeing is just horrible market breadth," Woods said.
Woods added that while the "Magnificent 7" stocks — Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Google parent Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — have done well, the divergence in their performance and that of the overall market is "getting a little bit too rich" for him.
See Also: <a href="https://www.benzinga.com/24/12/42696614/cathie-wood-takes-profit-on-hot-ai-stock-palantir-again-continues-to-sell-block-shares-amid-bitcoin-buzz">Cathie Wood Takes Profit On Hot AI Stock Palantir Again, Continues To Sell Block Shares Amid Bitcoin Buzz</a>
"Once we get to the new quarter, we're going to have some headwinds to deal with. We may see some of those Mag 7 names give back a little bit. I don't think the rotation will keep us from having a 10% correction."
"It's not going to be fun," he quipped.
Woods also pointed to uncertainty due to Trump's tariff plans as a possible headwind that could have an impact on the markets.
Elon Musk and Vivek Ramaswamy-led Department of Government Efficiency's (DOGE) plans to cut down federal spending could also result in an uptick in unemployment, said Woods.
Why It Matters: The potential for a market correction has been echoed by other financial experts.
Brian Arcese&nbsp;from&nbsp;Foord Asset Management&nbsp;has also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42133820/potential-healthy-correction-for-an-expensive-market-looms-as-us-economic-growth-and-earnings-slow-says-asset-manager-sp-500-nasdaq-futures-trade-lower-in-premarket">raised concerns</a> about the slowing U.S. economic growth and corporate earnings, which could trigger a correction if they continue to decelerate. Arcese pointed out that the S&amp;P 500 has been &#8220;expensive for quite a while,&#8221; with a price-to-earnings ratio exceeding 27.
Additionally,&nbsp;Jeremy Siegel, professor emeritus at the University of Pennsylvania's Wharton School, described a recent stock market downturn as a <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42570219/whartons-jeremy-siegel-calls-stock-sell-off-a-healthy-reality-check-market-was-overly-optimistic">&#8220;healthy&#8221; reaction</a> to the Federal Reserve&#8217;s cautious approach to future interest rate cuts.
The Fed&#8217;s decision to lower interest rates by a quarter percentage point led to declines across major Wall Street indexes, as investors had anticipated more aggressive rate reductions.
Billionaire investor&nbsp;David Einhorn <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42087680/billionaire-investor-david-einhorn-calls-it-most-expensive-market-of-all-time-as-sp-500-gains-4-since-trumps-win-really-really-pricey">characterized the market as &#8220;really, really, really pricey,&#8221;</a> noting that the Shiller cyclically adjusted price-to-earnings ratio is at one of the highest levels in a century.
Despite these high valuations, Einhorn clarified that this does not make him bearish, as asset prices can remain mispriced for extended periods.
Price Action: According to <a href="http://pro.benzinga.com">Benzinga Pro</a>, as of Friday&#8217;s pre-market session, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which mirrors the S&amp;P 500, has gained 1.68% over the past five days. Similarly, the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100 Index, has risen by 1.65% during the same period.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42682230/tech-bull-predicts-26-upside-for-apple-stock-sees-golden-era-of-growth-for-cupertino-due-to-multi-year-ai-driven-iphone-upgrade-cycle">Tech Bull Predicts 26% Upside For Apple Stock, Sees &#8216;Golden Era Of Growth&#8217; For Cupertino Due To Multi-Year AI-Driven iPhone Upgrade Cycle</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

AMZN

GOOG

GOOGL

MSFT

NVDA

US Stocks Likely Headed For 10% Correction, Says Top Strategist, Points Out 'Horrible Market Breadth:' Trump's Tariff Plans, Musk Co-Led DOGE Could Be Partially To Blame For Decline

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>)</h3>
<ul>
<li>Dividend Yield: 8.63%</li>
<li>Small Cap Consumer Research analyst Eric Beder reiterated a Buy rating with a price target of $23 on Dec. 18. This analyst has an accuracy rate of 63%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and cut the price target from $21 to $18 on Oct. 27. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Nov. 26, Guess? reported a year-over-year decrease in third-quarter adjusted EPS results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">latest GES news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/a966e0da-d6d8-4556-8a69-68ba12052b66" alt="" style="width:651px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>)</h3>
<ul>
<li>Dividend Yield: 13.47%</li>
<li>Guggenheim analyst Robert Drbul downgraded the stock from Buy to Neutral on Dec. 2. This analyst has an accuracy rate of 66%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Neutral rating and cut the price target from $18 to $14 on Nov. 27. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Nov. 27, Kohl&#8217;s reported worse-than-expected third-quarter EPS and sales, cut its FY24 EPS guidance, and projected a net sales decrease of 7%-8%.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">latest KSS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="896" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219.png" alt="" class="wp-image-709175" style="width:587px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219.png 896w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219-768x717.png 768w" sizes="(max-width: 896px) 100vw, 896px" /></a></figure>
<h3 class="wp-block-heading">Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>)</h3>
<ul>
<li>Dividend Yield: 7.73%</li>
<li>JP Morgan analyst John Ivankoe maintained a Neutral rating and slashed the price target from $19 to $14 on Nov. 12. This analyst has an accuracy rate of 75%.</li>
<li>Raymond James analyst Brian Vaccaro downgraded the stock from Outperform to Market Perform on Nov. 11. This analyst has an accuracy rate of 81%.</li>
<li>Recent News: On Nov. 8, the company reported third-quarter adjusted earnings per share of 21 cents, beating the street view of 20 cents. Quarterly revenues of $1.038 billion (down 3.8%) missed the analyst consensus of $1.042 billion.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">trend in BLMN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220.png" alt="" class="wp-image-709176" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220-768x716.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42697989/dow-edges-higher-in-thin-holiday-trading-fear-declines-among-us-investors-but-fear-greed-index-remains-in-fear-zone">Dow Edges Higher In Thin Holiday Trading As Tesla, Apple Surge: Investor Sentiment Improves, But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>

BLMN

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks With Over 7% Dividend Yields

Stock Pickers Better Know When They're Going To Sell

If you are interested in the stock market, maybe it is time to stop focusing on The Fed.

Don't Confuse Brains With A Bull Market, Or Price With Value

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

GeneDx (WGS) announced the appointment of Heidi Chen as chief legal officer, effective November 25. In her role, Heidi will report to Katherine Stu...

GeneDx appoints Heidi Chen as chief legal officer

Latest data shows the largest indicative borrow rate increases among liquid option names include: GlycoMimetics (GLYC) 26.88% +2.41, Endeavor Group...

Largest borrow rate increases among liquid names

Holiday Week With Healthy Chop (Technical Analysis)

GeneDx (WGS) announced Biogen (BIIB), Praxis Precision Medicines (PRAX) and Stoke Therapeutics (STOK) as the founding partners to its Patient Acces...

GeneDx expands access to exome testing for pediatric epilepsy patients

GeneDx Rides Revenue Surge, But Valuation Risks Loom

GeneDx: Possibly Turning A Profit In 2025 (Rating Downgrade)

These high-fliers are on the leading edge of innovation.

The Top 5 Mid Cap Stocks Of 2024

ADPT

ALAB

AMGN

ANET

AVTR

BIIB

BRKR

COIN

CORZ

DRUG

ETSY

EXAS

FOUR

GLYC

ILMN

JANX

MDXH

MYGN

NFLX

NTRA

OKLO

PACB

PLTR

PRAX

PSIX

QUBT

RBLX

RKLB

ROOT

RVTY

SGML

SMCI

SNDL

SOUN

SPYI

TACPF

TNSSF

TSLTF

WGSWW

ZETA

Press Releases

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

GeneDx to Participate in Upcoming Investor Conference

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

STOK

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Holdings

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

OPKO Health

Premier

Pennant Gr

Privia Health Gr

RadNet

Goldman Sachs

Wells Fargo

Craig-Hallum

TD Cowen

BTIG

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 마드리갈 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41648647" target="_blank" rel="noreferrer noopener">예상보다 좋은 실적</a>을 발표한 후 51.70% 상승했다.
2. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41583831" target="_blank" rel="noreferrer noopener">예상보다 좋은 3분기 재무 실적</a>과 2024 회계연도 매출 가이던스를 상향 조정했다고 발표한 후 34.20% 상승했다. 또한, 한 주주가 주당 91달러에 보통주 1억 7,500만 달러를 공모했다.
3. 글로벌스타(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>)의 주식은 회사가 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)과의 서비스 계약을 수정하여 새로운 위성과 인프라로 확장된 MSS 네트워크를 출시한다고 발표한 후 33.98% 상승했다.
4. 진Dx 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식은 회사가 예상보다 좋은 실적을 발표하고 <a href="https://www.benzinga.com//node/41602881" target="_blank" rel="noreferrer noopener">2024 회계연도 매출 가이던스를 상향 조정</a>한 후 31.17% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/wgs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
5. 넥스트래커(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>)의 주식은 회사가 2분기 실적을 발표하고 2025 회계연도 GAAP <a href="https://www.benzinga.com//node/41635816" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 상향 조정</a>한 후 25.91% 상승했다.
6. V.F. 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>)의 주식은 회사가 2분기 재무 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/41599918" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 25.82% 상승했다. 이 회사는 팀버랜드(Timberland)의 모기업이다.
7. 옴니셀(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>)의 주식은 회사가 3분기 실적을 발표하고 2024 회계연도 가이던스를 <a href="https://www.benzinga.com//node/41619987" target="_blank" rel="noreferrer noopener">예상치 이상으로 상향 조정</a>한 후 23.22% 상승했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/omcl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EB%B0%8F-%EC%97%90%EC%8A%A4%ED%8B%B0-%EB%A1%9C%EB%8D%94%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">슈퍼 마이크로 및 에스티 로더는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EB%A1%9C%EB%B8%94%EB%A1%9D%EC%8A%A4-%EB%B0%8F-%EA%B0%80%EB%AF%BC%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

진Dx 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)가 월요일 시장 마감 후 1분기 재무 결과를 보고한 후 주가가 급등했다. <a href="https://www.benzinga.com/pressreleases/24/04/g38502059/genedx-reports-first-quarter-2024-financial-results-and-business-highlights" target="_blank" rel="noopener">주요 내용</a>을 살펴보자.
주요 사항 (The Details): 진Dx(GeneDx)는 분기 손실을 주당 33센트로 보고했는데, 이는 분석가의 합의 손실 추정치인 67센트를 50.75%나 앞선 것이다.
이 회사는 분기별 매출이 6,242만 2,000달러로 분석가 합의 추정치인 4,946만 3,000달러를 26.2% 상회했으며 지난해 같은 기간보다 매출 4,313만 9,000달러보다 44.7% 증가한 수치라고 보고했다.
&#8220;우리의 강력한 1분기 실적은 엑솜(exome) 및 게놈(genome) 매출 증가, 평균 환급률 증가, 테스트에 대한 접근성 확대, 의미 있는 현금 소모 감소라는 세 가지 주요 조직 초점에 대한 우리의 지속적인 헌신을 반영한다&#8221;고 진Dx 의 CEO인 Katherine Stueland가 말했다.
&#8220;우리 팀의 1분기 성공적인 실행은 2024년 연간 매출 지침을 2억 3,500만~2억 4,500만 달러로 높이고 2025년에 수익성을 달성하겠다는 우리의 기대를 되풀이할 수 있다는 확신을 주었다.&#8221;
전망 (Outlook):  진Dx는 2024년 연간 매출 지침을 2억 2천만 달러-2억 3천만 달러에서 2억 3,500만-2억 4,500만 달러로 상향 조정했으며, 2024년 전체 조정 총 마진 프로필을 최소 50%에서 최소 60%로 확장했다.
관련 뉴스: <a href="https://www.benzinga.com/news/24/04/38499888/whats-going-on-with-super-micro-computer-stock-ahead-of-earnings">기업 실적 발표 전 슈퍼 마이크로 컴퓨터 주식의 동향</a>
WGS 주가 움직임: 진Dx의 주가는 월요일 시간 외 거래에서 30.18% 급등한 14.32달러에 거래되었다.
사진: Pixabay의 Gerd Altmann

Comments

GeneDx Hldgs

뉴스

에 대한 최신 뉴스 GeneDx Hldgs (NASDAQ:WGS) 주식

일요일, 11월 03, 2024

화요일, 4월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌